Publications Database

Arnold L. E. et al.

A 1.5-year follow-up of parent training and atomoxetine for attention-deficit hyperactivity disorder symptoms and noncompliant-disruptive behavior in autism.

Journal of Child and Adolescent Psychopharmacology

Read Abstract (New Window)

Hellings J. A. , Arnold L. E. , Han J. C. (2017)

Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline.

Experimental and Clinical Psychopharmacology

18(6), pp. 581-588.

Read Abstract (New Window)

Scahill L. et al. (2017)

Using a patient-centered outcome measure to test methylphenidate versus placebo in children with autism spectrum disorder.

Journal of Child and Adolescent Psychopharmacology

March, 27(2), pp. 125-131.

Read Abstract (New Window) Read Full (New Window)

Smith T. et al. (2016)

Atomoxetine and parent training for children with autism and attention-deficit-hyperactivity disorder: A 24-week extension study.

Journal of the Canadian Academy of Child and Adolescent Psychiatry

October, 55(10),

Read Abstract (New Window)

Vasa R. A. et al. (2016)

Assessment and treatment of anxiety in youth with autism spectrum disorders.

Pediatrics

February, 137

Read Full (New Window)

Anagnostou E. et al.

Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: A randomized clinical trial.

JAMA Psychiatry

Read Abstract (New Window)

Scahill L. et al. (2016)

Weight gain and metabolic consequences of risperidone in young children with autism spectrum disorder.

Journal of the American Academy of Child and Adolescent Psychiatry

May, 55(5), pp. 415-423.

Read Abstract (New Window)

Handen B. L. et al. (2015)

Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention deficit hyperactivity disorder.

Journal of the American Academy of Child and Adolescent Psychiatry

November, 54(11), pp. 905-915.

Read Abstract (New Window)

Aman M. G. et al. (2015)

Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial.

Journal of Child and Adolescent Psychopharmacology

August, 25(6), pp. 482-493.

Read Abstract (New Window) Read Full (New Window)

Aman M. G. et al. (2014)

A review of atomoxetine effects in young people with developmental disabilities.

Research in Developmental Disabilities

June, 35(6), pp. 1412-1424.

Read Full (New Window)